Base Year
Historical Year
Forecast Year
The dyslipidemia market size was valued at USD 10.2 billion in 2023, driven by the emphasis on preventing cardiovascular diseases across the major markets. The market is expected to grow at a CAGR of 6.7% during the forecast period of 2024-2032, with the values likely to rise from USD 10.8 billion in 2024 to USD 18.2 billion by 2032.
Dyslipidemia is a condition characterized by abnormal levels of lipids in the bloodstream. The most common forms of dyslipidemia involve high levels of bad cholesterol (LDL), triglycerides or low levels of good cholesterol (HDL). Untreated or severe dyslipidemia may lead to coronary artery disease (CAD) or peripheral artery disease (PAD). Based on cause, it can be categorized into two broad categories, primary dyslipidemia, which is inherited, and secondary dyslipidemia, which is caused by lifestyle factors. Treatment for dyslipidemia constitutes medications and lifestyle changes to control cholesterol levels naturally.
The increasing development of drugs and new therapeutics to treat the condition are increasingly contributing to the dyslipidemia market share. Ezetimibe is frequently used in combination with statins and has shown significant reductions in LDL cholesterol levels. Alirocumab (Praluent) is a human immunoglobulin G1 monoclonal antibody while Evolocumab is another monoclonal G2 antibody belonging to PCSK9 category. Bempedoic acid is another key agent that decreases LDL-C levels and showcases evidence of good tolerability and safety.
With advanced research and ongoing clinical trials, scientists are also working on using the potential of ASOs to impact mRNA and provide new avenues for the treatment of persistent disorders. Therefore, there is hope for treating primary dyslipidemia as well, especially with the rising advances in gene therapies. Such efforts in research and development, along with increased support from governments and healthcare organizations are likely to aid the dyslipidemia market demand in the coming years.
Market Breakup by Disease Type
General dyslipidemia
Market Breakup by Drug Type
Market Breakup by Drug Type
Market Breakup by Distributor Channel
Market Breakup by End User
Market Breakup by Region
With the rising prevalence of obesity, sedentary lifestyle habits, unhealthy dietary changes and tobacco consumption, the United States is at a higher risk of developing cardiovascular diseases. As a result, the region is expected to lead the dyslipidemia market share in the forecast period. The existence of regulatory authorities such as the FDA plays a pivotal part in maintaining the quality and efficacy of drugs being launched in the market. This can be a major factor in the growing market value in the region.
Owing to a high percentage of the geriatric population, Europe is another major market for dyslipidemia. With a robust healthcare ecosystem as well as proactive government, there are several awareness and educational campaigns launched in the region, explaining the maintenance of a healthy heart. The market growth is further enhanced by the presence of key healthcare and academic institutions that continuously conduct clinical trials to determine the efficacy of treatments.
In Asia Pacific, the dyslipidemia market growth is certain with the increasing investment in healthcare research and development infrastructure. The region is witnessing numerous mergers and acquisitions between native and foreign companies that aim to leverage the academic expertise pertaining to the region while offering the latest technologies to develop quality solutions. In addition, the government is also aiding market growth by facilitating easy accessibility of relevant to the people in need at affordable prices.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Drug Type |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 10.2 billion in 2023, driven by the emphasis on preventing cardiovascular diseases across the major markets.
The market is anticipated to grow at a CAGR of 6.7% during the forecast period of 2024-2032, likely to reach a market value of USD 18.2 billion by 2032.
The market demand is driven by the rising prevalence of sedentary lifestyles, obesity, increased substance indulgence, and unhealthy dietary habits.
The major market trend involves increasing investments in drug development and research activities to offer better solutions for patients.
The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
The disease type can be divided into General dyslipidemia, Hyperlipidemia, Combined hyperlipidemia, and Hypoalphalipoproteinemia.
The drug types can be divided into statin drugs and non-statin lipid–lowering drugs.
The distribution channels include hospital pharmacy, online pharmacy, and retail pharmacy, among others.
The end-users include hospitals, homecare, and specialty clinics, among others.
Key players involved in the market are Pfizer, Inc., Novartis AG, AstraZeneca plc, Amgen, Inc., Abbott Laboratories., Bayer AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Mylan N.V., Shionogi & Co., Ltd., Catabasis Pharmaceuticals, DAIICHI SANKYO COMPANY, LIMITED, GlaxoSmithKline plc, ESPERION Therapeutics, Inc., and Eli Lilly and Company.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share